Approach to the Critical Patient

Immediate recognition

Critical triggers for DHTR

Resuscitation priorities

Airway and oxygenation

Circulation and hemodynamics

Critical pitfalls

NEVER administer additional RBC transfusion in active hyperhemolysis

Immediate blood bank notification

Monitoring and escalation

Monitoring bundle

Escalation triggers

History

Transfusion history

Recent RBC transfusion context

Alloimmunization history

Presenting symptoms

Hemolysis symptom complex

Pain and systemic symptoms

Risk factors

Underlying hematologic disease

Sensitization risk factors

Past medical history

Medical background

Medication review

Physical Exam

Vital signs

Hemodynamic assessment

Skin and mucous membranes

Hemolysis signs

Additional skin findings

Abdominal exam

Organomegaly

Cardiovascular and respiratory exam

Cardiac exam

Respiratory exam

Neurologic exam

Neurologic assessment

Urine inspection

Urinary findings

Differential Diagnosis

Life-threatening mimics

Immediately dangerous diagnoses

Hematologic mimics

Hemolytic conditions

Sickle cell specific mimics

Other mimics

Non-immune hemolysis

Laboratory Tests

Core hemolysis panel

Complete blood count with differential

Hemolysis markers

Immunologic testing

Blood bank workup

End-organ and metabolic labs

Renal function

Coagulation studies

Sickle cell specific labs

Additional labs

Diagnostic Tests

Scoring Systems

DHTR severity stratification

MRI

Brain MRI indications in DHTR

CT

CT head

Ultrasound

Abdominal ultrasound

Point-of-care cardiac ultrasound

Duplex ultrasound of extremities

Disposition

Admission criteria

Indications for inpatient admission

ICU criteria

ICU admission triggers

Transfer criteria

Transfer to specialized center

Discharge criteria

Safe discharge requirements

Consultations

Required consultations

Treatment

Immediate stabilization

Stop-transfusion protocol

Treatment for mild DHTR (no hyperhemolysis)

Supportive management

Treatment for severe DHTR with hyperhemolysis (ASH 2020 Guidelines)

First-line immunosuppressive therapy

Second-line: eculizumab

Rituximab for alloantibody prevention

Supportive erythropoiesis

Stimulating bone marrow recovery

Transfusion management if absolutely required

Indications for transfusion despite DHTR

Special Populations

Pregnancy

DHTR in pregnancy

Geriatric

DHTR in older adults

Pediatrics

DHTR in children

Background

Epidemiology

Incidence and prevalence

Mortality and morbidity

Pathophysiology

Immune mechanism

Hyperhemolysis mechanism

Implicated antibody systems

Therapeutic Considerations

Treatment rationale

Prevention strategies

Patient Discharge Instructions

copy discharge instructions

Discharge teaching for DHTR

Antibody identification card

Medications after discharge

Follow-up instructions

Return to emergency department immediately if

References

Guidelines and key sources

Primary society guidelines

Landmark studies and reviews

Key references

Pediatric and SCD-specific references

Pediatric and SCD literature

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.